This receipt is still in the Pro early-access window — public in 23h.
Upgrade to Pro for 24-48h early access on every new drop + weekly newsletter + category alerts.
Upgrade — $9.99/mo
On May 1–4, 2026, the $7.4 billion Purdue Pharma/Sackler opioid settlement went into effect after years of litigation and a Supreme Court reversal of an earlier deal. The Sacklers are permanently barred from selling opioids in the U.S., paid over $1.5 billion immediately with hundreds of millions more through 2029, and — critically — Purdue and the Sacklers must make public more than 30 million documents about their opioid business.
“On May 1–4, 2026, the $7.4 billion Purdue Pharma/Sackler opioid settlement went into effect after years of litigation and a Supreme Court reversal of an earlier deal. The Sacklers are permanently barred from selling opioids in the U.S., paid over $1.5 billion immediately with hundreds of millions more through 2029, and — critically — Purdue and the Sacklers must make public more than 30 million documents about their opioid business.”
In early May 2026, the long-fought $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family, went into effect. State attorneys general confirmed the effective date, capping a saga that ran through Purdue's 2019 bankruptcy, a 2024 Supreme Court decision striking down an earlier deal that had shielded the Sacklers, and a November 2025 bankruptcy-court confirmation of the revised plan.
The Sacklers are paying more than $1.5 billion immediately, followed by roughly $500 million in May 2027, $500 million in May 2028, and $400 million in May 2029. Purdue itself is paying about $900 million up front. The total package reaches $7.4 billion, with funds directed to states for opioid abatement.
The settlement permanently bars the Sackler family from selling opioids in the United States. Purdue's manufacturing operations are being transferred to a new entity, Knoa Pharma LLC, under independent oversight — ending the family's direct control of OxyContin's maker.
The most consequential term for the public record: Purdue and the Sacklers must release more than 30 million documents related to their opioid business. These internal records — marketing strategies, sales-force directives, communications about addiction risk — are precisely the kind of primary-source material that documents what a company and a family knew, and when, about the drug at the center of an epidemic that has killed hundreds of thousands of Americans.
Get the 5 biggest receipts every week, straight to your inbox — plus an exclusive PDF: The Top 10 Conspiracy Theories Proven True in 2025-2026. No spam. No agenda. Just the papers they couldn't hide.
You just read "Sacklers Finally Pay: $7.4B Opioid Deal Takes Effect, 30 Mil…". We send ones like this every week.
No one's said anything yet. Be the first to drop your take.
Beat the odds
This had a 0.3% chance of leaking — someone talked anyway.
Conspirators
~300Network
Secret kept
2.4 years
Time to 95% exposure
500+ years
